Credit Suisse Group began coverage on shares of Uniqure (NASDAQ:QURE) in a research report sent to investors on Tuesday, Briefing.com Automated Import reports. The brokerage issued an outperform rating and a $76.00 price objective on the biotechnology company’s stock.

Other analysts have also recently issued reports about the company. Chardan Capital reissued a buy rating on shares of Uniqure in a research note on Tuesday, September 3rd. Stifel Nicolaus assumed coverage on Uniqure in a research note on Friday, October 11th. They set a buy rating and a $79.00 target price for the company. Guggenheim cut Uniqure from a buy rating to a neutral rating in a research note on Monday, July 29th. Zacks Investment Research raised Uniqure from a hold rating to a buy rating and set a $42.00 target price for the company in a research note on Thursday, October 3rd. Finally, Sanford C. Bernstein initiated coverage on shares of Uniqure in a research note on Tuesday, September 24th. They set an outperform rating and a $73.00 price target for the company. Two analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $74.53.

NASDAQ QURE opened at $53.63 on Tuesday. The business has a 50 day simple moving average of $44.99 and a 200 day simple moving average of $58.07. Uniqure has a 52-week low of $21.98 and a 52-week high of $82.49. The company has a debt-to-equity ratio of 0.19, a quick ratio of 14.33 and a current ratio of 14.33. The stock has a market cap of $2.22 billion, a price-to-earnings ratio of -22.92 and a beta of 0.84.

Uniqure (NASDAQ:QURE) last posted its earnings results on Monday, October 28th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.23. Uniqure had a negative return on equity of 51.12% and a negative net margin of 1,670.86%. The business had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $2.24 million. On average, analysts predict that Uniqure will post -3 EPS for the current year.

In other news, CEO Matthew C. Kapusta sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $56.48, for a total transaction of $451,840.00. Following the completion of the transaction, the chief executive officer now directly owns 391,230 shares of the company’s stock, valued at approximately $22,096,670.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Alexander Edward Kuta III sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $47.26, for a total transaction of $189,040.00. Following the transaction, the vice president now directly owns 30,578 shares of the company’s stock, valued at $1,445,116.28. The disclosure for this sale can be found here. Insiders have sold a total of 36,769 shares of company stock valued at $1,759,426 over the last ninety days. Company insiders own 2.91% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Griffin Asset Management Inc. bought a new position in shares of Uniqure in the second quarter valued at $39,000. US Bancorp DE grew its stake in shares of Uniqure by 275.5% in the second quarter. US Bancorp DE now owns 582 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 427 shares in the last quarter. Rockefeller Capital Management L.P. bought a new position in shares of Uniqure in the second quarter valued at $78,000. Botty Investors LLC bought a new position in shares of Uniqure in the second quarter valued at $78,000. Finally, Aperio Group LLC bought a new position in shares of Uniqure in the second quarter valued at $83,000. 60.89% of the stock is owned by institutional investors.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Featured Story: What is the cash asset ratio?

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.